Scribe Therapeutics announced new preclinical data at the American Heart Association 2026 Scientific Sessions demonstrating that their lead therapy STX-1150 provides persistent LDL cholesterol control for at least two years after a single dose in primates. Additionally, their gene editing therapy STX-1200 showed robust and durable reduction of lipoprotein(a), a major genetic risk factor for cardiovascular disease, in preclinical models. These advances highlight Scribe's potential to offer long-term treatments for heart disease risk factors using CRISPR-based technologies. The company is currently conducting a Phase 1 trial for STX-1150 and plans further development of STX-1200.
Scribe Therapeutics' gene editing and epigenetic silencing therapies are the focus, with Pluang's Health-sector snapshot providing market context. Among 150 priced US health stocks on Pluang, 121 rose and 23 fell as of Nov 04, 2026 19:41 WIB. Notably, Charles River Laboratories Intl. Inc (CRL) dropped 6.21% to USD 330.01 with a typical hold time of 35 days, contrasting with Canopy Growth Corp (CGC) which gained 6.13% to USD 0.75 and saw 100% buy orders and a 40-day hold time, while Novo Nordisk A/S (NVO) rose 5.92% to USD 42.57 with 90% buy orders and a notably longer hold time of 118 days.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
